Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis.

Cancers·2026
Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

2025 Advancing Cell and Gene Therapies for Cancer post-meeting report.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

HSR26-206: The Future of Oncology Research: Replacing Case Report Forms With mCODE-Aligned Electronic Health Record Data for Clinical Trial Data Curation (Alliance).

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Conversion of Failed Ankle Arthrodesis to Total Ankle Arthroplasty Using a Novel Custom Fibula in a Global Pes Cavus Deformity.

Foot & ankle specialist·2026
Same author

Comparison of clinical, radiographic and genomic alterations between histologic and molecular glioblastoma, <i>IDH</i>-wildtype.

Neuro-oncology advances·2026

Related Experiment Video

Updated: Jun 21, 2026

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Vorinostat in solid and hematologic malignancies.

David Siegel1, Mohamad Hussein, Chandra Belani

  • 1Hackensack University Medical Center, Hackensack, NJ, USA. dsiegel@humed.com

Journal of Hematology & Oncology
|July 29, 2009
PubMed
Summary
This summary is machine-generated.

Vorinostat, a histone deacetylase inhibitor, is well-tolerated in solid and hematologic malignancies. This review highlights its safety and efficacy as monotherapy or combination treatment for various cancers.

Related Experiment Videos

Last Updated: Jun 21, 2026

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Vorinostat (Zolinza) is a histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.
  • It has been investigated for use in various solid and hematologic malignancies.

Purpose of the Study:

  • To review evidence on vorinostat's use in solid and hematologic malignancies.
  • To collate tolerability data from clinical trials of vorinostat.

Main Methods:

  • Pooled analysis of vorinostat clinical trial data from 498 patients.
  • Review of adverse events (AEs) from monotherapy and combination therapy trials.

Main Results:

  • Vorinostat was well-tolerated as monotherapy or combination therapy.
  • Common monotherapy AEs included fatigue, nausea, and diarrhea; Grade 3/4 AEs included fatigue and thrombocytopenia.
  • Combination therapy showed a similar AE profile, mostly Grade 2 or less.

Conclusions:

  • Vorinostat demonstrates preliminary anticancer activity in various malignancies.
  • Ongoing studies are evaluating vorinostat in combination therapies for diverse cancer types.